pharma · Solid Tumor, Adult · Advanced Soft-tissue Sarcoma · MNPR
Monopar Therapeutics
Monopar Therapeutics patent portfolio — 3 USPTO pharmaceutical patents (A61K/A61P) with grant dates, status, and loss-of-exclusivity filters.
Company details
- Status
- Public
- HQ
- Wilmette, USA
- Founded
- 2015
- Employees
- 22
- Programs
- 4
- Drugs
- 3
- Patents
- 3
Monopar Therapeutics patents
3 pharmaceutical patents indexed for Monopar Therapeutics. 0 expire within 24 months.
Monopar Therapeutics has 3 pharmaceutical patents in our USPTO PatentsView index (A61K/A61P). 0 expire within 24 months — use filters for patent-cliff planning.
Patent portfolio
-
US 11090290
Clonidine and/or clonidine derivatives for use in the prevention of skin injury resulting from radiotherapy
granted -
US 10675271
Clonidine and/or clonidine derivatives for use in the prevention and/or treatment of adverse side effects of chemotherapy
granted -
US 10450340
3′-deamino-3′-(2″-pyrroline-1″-yl)-5-imino-13-deoxyanthracyclines and methods of preparation
granted
Frequently asked questions
How many patents does Monopar Therapeutics have?
3 published patents match the current filter (all indexed). The full portfolio is indexed from USPTO PatentsView (A61K/A61P).
When do Monopar Therapeutics patents expire?
0 patents in the full portfolio expire within 24 months. Use the expiring filters above or open individual patent pages for grant and expiration dates.